Navigation Links
Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinson's Disease
Date:3/27/2009

NEW YORK, March 27 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation announced that it has awarded approximately $2.1 million total to seven research teams working to improve drug delivery for Parkinson's disease.

The funding was awarded under the Foundation's Improving Delivery of Parkinson's Disease Therapeutics to the Brain. The program is designed to address two major challenges to the development of transformative treatments for Parkinson's disease: the need for non-invasive drug delivery technologies allowing therapeutics to cross the blood-brain barrier, and the need to more precisely understand how molecules move inside the central nervous system in order to target treatments to specific regions of the brain.

Funded projects are listed below. Full information on funded projects, including grant abstracts and researcher bios, is available on the Foundation's Searchable Database of Funded Grants.

Image-guided Gene Delivery for Parkinson's

Krysztof Bankiewicz, M.D., Ph.D., University of California, San Francisco

Convection Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Human Parkinson's Disease

Jeff Elias, M.D., University of Virginia, and Russell Lonser, M.D., National Institute of Neurodegenerative Disease and Stroke

Real-time Monitoring of Targeting, Delivery, and Spread of Therapeutic Agents in the Brain

Samir Jafri, Ph.D., University of Maryland, Baltimore, and Cha-Min Tang, M.D., Ph.D., University of Maryland School of Medicine

Utilizing Novel Tracers to Determine the Distribution of Therapeutic Agents In Vivo

RamakrishnaVenugopalan, Ph.D., Codman and Shurtleff, Inc.

Deep Brain Imaging to Determine the Movement of Compounds Relevant to Parkinson's Disease

Mark Saltzman, Ph.D., and Michael Levene, Ph.D., Yale University

Novel Antibodies for the Delivery of Parkinson's Therapeutics

Eric Shusta, Ph.D., and Clive Svendson, Ph.D., University of Wisconsin, Madison

Intranasal Gene Therapy: Next Steps

Barbara Lee Waszczak, Ph.D., Northeastern University

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $142 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
(Date:4/28/2016)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... the development of oral drug delivery systems, announced today that ... presented by Joseph Gunnar & Co. LLC, taking ... . Nadav Kidron , CEO of Oramed, will ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/27/2016)...  Hologic, Inc. (Nasdaq: HOLX ) ... fiscal second quarter ended March 26, 2016.  GAAP ... 41.2%, and non-GAAP diluted EPS of $0.47 increased ... a reported basis, and 6.3% on a constant ... good quarter, highlighted by 14.6% growth in non-GAAP ...
Breaking Medicine Technology:
(Date:4/29/2016)... Dobbs Ferry, New York (PRWEB) , ... April 30, 2016 , ... ... and the Dobbs Ferry campus. The following programs will be expanding due to ... Resources Management (HRM). The expansion will begin this summer. , School ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula ... brain and mood optimization products to the store is just one more way ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... . Dr. Bernie Siegel, author of a plethora of essential books-to-read for ...
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by ... congenital diaphragmatic hernia have better survival rates if surgery is performed early. Approximately ... where the diaphragm fails to form completely, letting abdominal organs into the chest ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... products, announces the Gyrociser, an exercise invention which aids in proper muscle development. ... Scott Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened ...
Breaking Medicine News(10 mins):